In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially high CV disease risk has increased.

An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.

Although most skin problems are harmless, a minor one can become serious in people who have diabetes. Whether it’s the common skin tag or more tongue-twisting things like necrobiosis lipoidica, you should be aware of the dermatologic conditions that could be precursors or signs of diabetes in your patients. With images and descriptions, this resource will provide a great review of the conditions.

The data was presented to the FDA, which reported 789 cases of myocarditis/pericarditis – predominantly in males – after receiving the Pfizer/BioNTech and Moderna vaccines, most commonly after the second dose. Symptoms included chest pain, elevated cardiac enzymes, ST or T wave changes, dyspnea, and abnormal echocardiography/imaging for those ages 30 years and younger.

Both men and women can be affected by medications that cause unwanted side effects, one of which can be sexual dysfunction. It’s important to talk to your patients about how to manage their primary conditions while working with them to alleviate the problems associated with these common medications that affect sex drive.

There have been few studies that have used validated measures to investigate the sexual harassment of physicians, never mind the sexual harassment of oncologists. According to the authors, this report is the first of its kind to examine the prevalence and types of sexual harassment experienced by oncologists, measuring their work experiences in three forms: sexual attention, sexual coercion, and gender harassment.